RxDoctor Payments Data

Paul Gobourne

Family · Washington, DCNPI 1245417492

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $679, more than ten times the $57 reported in 2022.

$1,536in general payments, 2019–2025

Across 52 payments — averaging $29.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$354
  • Reapplix Inc.$261
  • Tactile Systems Technology Inc$257
  • Smith+Nephew$141
  • Kerecis Limited$141
  • Convatec Inc.$115
  • plus $267 from 7 others

What the payments were for

  • Food & beverage$1,536100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,536 in reported general payments places this provider in the 85th percentile of 392 family providers in District of Columbia.

See all family providers in District of Columbia

Medicare billing

Part B allowed, 2024
$31,079
Medicare patients
81
Services billed
493

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciprofloxacin Hcl16$270
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17$201
Doxycycline Monohydrate14$191

Paid to pharmacies, not to this prescriber.

Other family in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →